PPIL4

Across TCGA pan-cancer cohorts, PPIL4 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated PPIL4 data layer compared with 23 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PPIL4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated PPIL4 expression acts as an unfavorable survival marker, although some lineages such as LUAD and CCRCC show a favorable association.

HNSC, LUAD, and CCRCC are the cancer types where PPIL4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	All	0.530	0.749	.005	37	view →
LUAD	DFS	Median	All	0.846	0.624	.001	26	view →
CCRCC	DFS	Median	III,IV	0.818	0.244	.031	11	view →
OV	DFS	Median	All	0.849	1.000	.023	4	view →
GBM	OS	Quartile	All	0.555	0.349	.043	2	view →
LSCC	DFS	Median	III,IV	0.882	1.000	.048	1	view →
PDAC	OS	Tertile	All	0.358	0.546	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

PPIL4–HNSC (DFS)

Open the HNSC breakdown →